Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Aurobindo Pharma Ltd.
Change Company   
BSE Code 524804
ISIN Demat INE406A01037
Book Value 369.16
NSE Code AUROPHARMA
Dividend Yield % 0.00
Market Cap 691821.85
P/E 34.24
EPS 34.79
Face Value 1  
02-Feb-2026 Clarification On Significant Volume Movement In ...
02-Feb-2026 Aurobindo Pharma informs about earnings call
01-Feb-2026 Clarification sought from Aurobindo Pharma Ltd
30-Jan-2026 Aurobindo Pharma informs about board meeting
09-Jan-2026 Aurobindo Pharma’s arm receives Notice of Complia...
02-Jan-2026 Aurobindo’s arm approves acquisition of Khandelwa...
02-Jan-2026 Aurobindo gains as its arm approves acquisition o...
29-Dec-2025 Aurobindo Pharma’s arm to terminate agreement wit...
24-Dec-2025 Aurobindo Pharma gains as its arm to acquire 20% ...
23-Dec-2025 Aurobindo Pharma’s arm to acquire 20% additional ...
18-Dec-2025 USFDA concludes inspection at unit-IV of Aurobind...
18-Dec-2025 Aurobindo Pharma informs about updates
15-Dec-2025 Aurobindo Pharma’s arm gets 3 observations from U...
02-Dec-2025 Aurobindo Pharma informs about newspaper publicat...
27-Nov-2025 Aurobindo Pharma informs about press release
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.